British Journal of Clinical Pharmacology themed edition: Immuno‐oncology

The September edition of the British Journal of Clinical Pharmacology includes several articles covering immunopharmacology in cancer therapy (e.g. immune checkpoint inhibitors, chimeric antigen receptor T-cell [CAR-T] therapies).

Source:

British Journal of Clinical Pharmacology

Resource links:

Taking the brake off the immune system: Hypotheses, trials, tribulations, and the evolving discipline of clinical immunopharmacology

Chimeric antigen receptor T‐cell therapies: Optimising the dose

Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies

Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy

Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors

Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches

Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response

Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?

Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors

Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy